BTI
TLX

Blue Trust Inc’s Telix Pharmaceuticals TLX Stock Holding History

Blue Trust Inc’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55K Hold
742
– – ﹤0.01% 1901
2026
Q1 		$7.1K Sell
742
-2,344
-76% -$17.9K ﹤0.01% 1914
2025
Q4 		$23.1K Buy
3,086
+1,880
+156% +$18.1K ﹤0.01% 1637
2025
Q3 		$11.5K Buy
+1,206
New +$14.8K ﹤0.01% 1831

Other funds holding TLX

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Blue Trust Inc's TLX Position: Q2 2026 in Review

Blue Trust Inc held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 742 shares worth $8.55K. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

Blue Trust Inc first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. The position peaked at $23.1K in Q4 2025. 20 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Blue Trust Inc held 742 shares of Telix Pharmaceuticals worth $8.55K as of Q2 2026.
  • Blue Trust Inc left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1901 holding.
  • Blue Trust Inc first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Blue Trust Inc's Telix Pharmaceuticals position peaked at $23.1K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.